-+ 0.00%
-+ 0.00%
-+ 0.00%

Starling Oncology forecasts FY2026 revenue of $650-670 million

PUBT·09/09/2026 10:38:12
Listen to the news
Starling Oncology forecasts FY2026 revenue of $650-670 million
  • Starling Oncology forecast FY26 revenue of USD 650-670 million, based on guidance reiterated in its Aug. 6, 2026 2Q26 release.
  • Adjusted EBITDA expected at USD 2-7 million for FY26, implying a low single-digit margin on the revenue outlook.
  • Forecast follows FY25 revenue of USD 503 million, with revenue mix led by specialty pharmacy at 54%.
  • Growth backdrop includes 2.3 million value-based care lives under contract, 60+ payor contracts, 300,000+ encounters in 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Starling Oncology Inc. published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.